Heterogeneity of Breast Cancer Associations with Common Genetic Variants in FGFR2 according to the Intrinsic Subtypes in Southern Han Chinese Women
Table 1
Characteristics of controls and breast cancer cases in the Southern China Breast Cancer Genetics Study.
Variables
Overall cases versus controls
Breast tumor subtypes
Controls ()
Cases ()
Luminal-B
Luminal-A
ER−HER2+
Triple negative
Age (years [mean ± SD])
45.2 ± 10.7
48.5 ± 9.5
<0.001
47.3 ± 9.7
48.0 ± 9.3
50.4 ± 9.2
49.1 ± 9.8
0.05
Body mass index (kg/m2 [mean ± SD])
23.6 ± 5.1
23.1 ± 5.0
0.07
22.7 ± 5.0
23.2 ± 5.3
23.0 ± 4.8
23.1 ± 5.0
0.77
Age at menarche (years [%])
≤13
76.5
73.4
0.17
71.7
71.9
74.4
77.6
0.66
>13
23.5
26.6
28.3
28.1
25.6
22.4
Nulliparous (%)
13.4
11.8
0.38
11.5
14.8
8.5
8.6
0.2
Age at first full-term pregnancy among parous women (years [%])
≤30
97.2
86.4
<0.001
80.5
87.8
84.6
90.5
0.12
>30
2.8
13.6
19.5
12.2
15.4
9.5
Menopausal status and HT (%)
Premenopausal
33.9
33.7
0.003
28.3
38.8
28.2
32.8
0.06
Postmenopausal, never HT
8.8
14.9
23.0
10.6
19.7
12.1
Postmenopausal, former HT
22.3
19.7
21.2
19.0
20.5
19.0
Postmenopausal, current HT
34.9
31.7
27.4
31.6
31.6
36.2
Abbreviations: SD, standard deviation; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HT, hormonal therapy including estrogen therapy or estrogen plus progestin therapy.
